Predictors of Super/Poor Omalizumab Response in Chinese Refractory Chronic Spontaneous Urticaria
Abstract
Introduction: Omalizumab is an effective treatment for antihistamine-refractory chronic spontaneous urticaria (CSU), although treatment responses vary significantly. While fast and slow responders are well characterized, the profile of super responders (SRs) remains poorly understood. This study aimed to identify clinical and laboratory predictors of super response (SR) and poor/non-response (PR) to omalizumab in refractory CSU. METHODS: This retrospective study analyzed 307 CSU patients treated with omalizumab at a UCARE center between January 2023 and December 2024. SR was defined as achieving Urticaria Activity Score (UAS) = 0 within 1 week and sustained control (UAS7 ≤6, Urticaria Control Test [UCT] >12); PR was defined as UCT
Fields of Study & Subjects
Urticaria and Related Conditions
Drug-Induced Adverse Reactions
Coagulation
Bradykinin
Polyphosphates
and Angioedema
Publication details
- Journal / source
- Dermatology
- Publisher
- S. Karger AG
- Volume
- 242
- Issue
- 4
- Pages
- 471–481
- Publication date
- 18 April 2026
- Language
- EN